K J L Choo1, E Simons, Aziz Sheikh. 1. Allergy & Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, UK.
Abstract
BACKGROUND: Anaphylaxis is a serious hypersensitivity reaction that is rapid in onset and may result in death. A number of guidelines recommend glucocorticoids for the treatment of people experiencing anaphylaxis. OBJECTIVES: We sought to assess the benefits and harms of glucocorticoid treatment during episodes of anaphylaxis. METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, Issue 3), MEDLINE (Ovid) (1966 to September 2009), EMBASE (Ovid) (1988 to September 2009), CINAHL (EBSCOhost) (to September 2009) and The Science Citation Index Expanded (SCI-EXPANDED) (1945 to September 2009). We also searched the UK National Research Register and websites listing ongoing trials and contacted international experts in anaphylaxis in an attempt to locate unpublished material. We sought to include randomized and quasi-randomized controlled trials comparing glucocorticoids with any control (either placebo, adrenaline (epinephrine), an antihistamine, or any combination of these). Two authors independently assessed articles for inclusion. RESULTS: None of the 2496 reports identified satisfied the inclusion criteria. CONCLUSIONS: We conclude that there is no evidence from high-quality studies for the use of steroids in the emergency management of anaphylaxis. Therefore, we can neither support nor refute the use of these drugs for this purpose.
BACKGROUND: Anaphylaxis is a serious hypersensitivity reaction that is rapid in onset and may result in death. A number of guidelines recommend glucocorticoids for the treatment of people experiencing anaphylaxis. OBJECTIVES: We sought to assess the benefits and harms of glucocorticoid treatment during episodes of anaphylaxis. METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, Issue 3), MEDLINE (Ovid) (1966 to September 2009), EMBASE (Ovid) (1988 to September 2009), CINAHL (EBSCOhost) (to September 2009) and The Science Citation Index Expanded (SCI-EXPANDED) (1945 to September 2009). We also searched the UK National Research Register and websites listing ongoing trials and contacted international experts in anaphylaxis in an attempt to locate unpublished material. We sought to include randomized and quasi-randomized controlled trials comparing glucocorticoids with any control (either placebo, adrenaline (epinephrine), an antihistamine, or any combination of these). Two authors independently assessed articles for inclusion. RESULTS: None of the 2496 reports identified satisfied the inclusion criteria. CONCLUSIONS: We conclude that there is no evidence from high-quality studies for the use of steroids in the emergency management of anaphylaxis. Therefore, we can neither support nor refute the use of these drugs for this purpose.
Authors: A Wesley Burks; Stacie M Jones; Joshua A Boyce; Scott H Sicherer; Robert A Wood; Amal Assa'ad; Hugh A Sampson Journal: Pediatrics Date: 2011-10-10 Impact factor: 7.124
Authors: Joshua A Boyce; Amal Assa'ad; A Wesley Burks; Stacie M Jones; Hugh A Sampson; Robert A Wood; Marshall Plaut; Susan F Cooper; Matthew J Fenton; S Hasan Arshad; Sami L Bahna; Lisa A Beck; Carol Byrd-Bredbenner; Carlos A Camargo; Lawrence Eichenfield; Glenn T Furuta; Jon M Hanifin; Carol Jones; Monica Kraft; Bruce D Levy; Phil Lieberman; Stefano Luccioli; Kathleen M McCall; Lynda C Schneider; Ronald A Simon; F Estelle R Simons; Stephen J Teach; Barbara P Yawn; Julie M Schwaninger Journal: J Allergy Clin Immunol Date: 2010-12 Impact factor: 10.793
Authors: Carsten Lott; Anatolij Truhlář; Anette Alfonzo; Alessandro Barelli; Violeta González-Salvado; Jochen Hinkelbein; Jerry P Nolan; Peter Paal; Gavin D Perkins; Karl-Christian Thies; Joyce Yeung; David A Zideman; Jasmeet Soar Journal: Notf Rett Med Date: 2021-06-10 Impact factor: 0.826